A detailed history of Legal & General Group PLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 37,418 shares of MIRM stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,418
Previous 28,645 30.63%
Holding current value
$1.45 Million
Previous $719,000 77.89%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.57 - $34.85 $206,779 - $305,739
8,773 Added 30.63%
37,418 $1.28 Million
Q1 2024

Jul 01, 2024

BUY
$24.92 - $30.02 $33,542 - $40,406
1,346 Added 4.93%
28,645 $719,000
Q1 2024

May 14, 2024

SELL
$24.92 - $30.02 $34,937 - $42,088
-1,402 Reduced 4.88%
27,299 $685,000
Q4 2023

Feb 15, 2024

BUY
$27.14 - $34.93 $164,386 - $211,571
6,057 Added 26.75%
28,701 $847,000
Q3 2023

Nov 14, 2023

BUY
$24.63 - $32.85 $45,171 - $60,246
1,834 Added 8.81%
22,644 $715,000
Q2 2023

Aug 14, 2023

BUY
$23.51 - $30.09 $306,358 - $392,102
13,031 Added 167.52%
20,810 $538,000
Q1 2023

May 15, 2023

BUY
$19.19 - $24.1 $9,556 - $12,001
498 Added 6.84%
7,779 $186,000
Q3 2022

Nov 14, 2022

BUY
$19.98 - $29.44 $13,946 - $20,549
698 Added 10.6%
7,281 $153,000
Q2 2022

Aug 22, 2022

BUY
$18.42 - $27.5 $115,972 - $173,140
6,296 Added 2193.73%
6,583 $128,000
Q3 2021

Nov 15, 2021

SELL
$13.95 - $20.18 $906 - $1,311
-65 Reduced 18.47%
287 $6,000
Q2 2021

Aug 12, 2021

SELL
$15.84 - $20.6 $2,249 - $2,925
-142 Reduced 28.74%
352 $6,000
Q3 2020

Nov 13, 2020

SELL
$18.4 - $26.59 $5,961 - $8,615
-324 Reduced 39.61%
494 $9,000
Q1 2020

May 14, 2020

BUY
$9.38 - $23.79 $2,504 - $6,351
267 Added 48.46%
818 $11,000
Q4 2019

Feb 13, 2020

BUY
$6.84 - $25.9 $3,768 - $14,270
551 New
551 $14,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.43B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.